Literature DB >> 11448944

Functional analysis of neurofibromatosis 2 (NF2) missense mutations.

D H Gutmann1, A C Hirbe, C A Haipek.   

Abstract

Neurofibromatosis 2 (NF2) is a tumor predisposition syndrome in which affected individuals develop nervous system tumors at an increased frequency. The most common tumor in individuals with NF2 is the schwannoma, which is composed of neoplastic Schwann cells lacking NF2 gene expression. Moreover, inactivation of the NF2 gene is observed in nearly all sporadic schwannomas, suggesting that the NF2 gene is a critical growth regulator for Schwann cells. In an effort to gain insights into the function of the NF2 gene product, merlin or schwannomin, we performed a detailed functional analysis of eight naturally occurring non-conservative missense mutations in the NF2 gene. Using a regulatable expression system in rat schwannoma cells, we analyzed proliferation, actin cytoskeleton-mediated events and merlin folding. In this report, we demonstrate that mutations clustered in the predicted alpha-helical region did not impair the function of merlin whereas those in either the N- or C-terminus of the protein rendered merlin inactive as a negative growth regulator. These results suggest that the key functional domains of merlin lie within the highly conserved FERM domain and the unique C-terminus of the protein.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448944     DOI: 10.1093/hmg/10.14.1519

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  17 in total

1.  The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.

Authors:  Anne-Marie Bashour; J-J Meng; Wallace Ip; Mia MacCollin; Nancy Ratner
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

Review 2.  The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.

Authors:  M E Baser; L Kuramoto; R Woods; H Joe; J M Friedman; A J Wallace; R T Ramsden; S Olschwang; E Bijlsma; M Kalamarides; L Papi; R Kato; J Carroll; C Lázaro; F Joncourt; D M Parry; G A Rouleau; D G R Evans
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

3.  Microtubule-mediated transport of the tumor-suppressor protein Merlin and its mutants.

Authors:  Lorena B Benseñor; Kari Barlan; Sarah E Rice; Richard G Fehon; Vladimir I Gelfand
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

Review 4.  Regulation of the Hippo pathway and implications for anticancer drug development.

Authors:  Hyun Woo Park; Kun-Liang Guan
Journal:  Trends Pharmacol Sci       Date:  2013-09-16       Impact factor: 14.819

5.  Identification of novel fusion transcripts in meningioma.

Authors:  A Basit Khan; Ron Gadot; Arya Shetty; James C Bayley; Caroline C Hadley; Maria F Cardenas; Ali Jalali; Akdes S Harmanci; Arif O Harmanci; David A Wheeler; Tiemo J Klisch; Akash J Patel
Journal:  J Neurooncol       Date:  2020-09-19       Impact factor: 4.130

6.  Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus.

Authors:  Wei Li; Liru You; Jonathan Cooper; Gaia Schiavon; Angela Pepe-Caprio; Lu Zhou; Ryohei Ishii; Marco Giovannini; C Oliver Hanemann; Stephen B Long; Hediye Erdjument-Bromage; Pengbo Zhou; Paul Tempst; Filippo G Giancotti
Journal:  Cell       Date:  2010-02-19       Impact factor: 41.582

Review 7.  Molecular pathogenesis of meningiomas.

Authors:  Arie Perry; David H Gutmann; Guido Reifenberger
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

8.  Loss of heterozygosity on long arm of chromosome 22 in sporadic colorectal carcinoma.

Authors:  Chong-Zhi Zhou; Zhi-Hai Peng; Fang Zhang; Guo-Qiang Qiu; Lin He
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

9.  Mouse models of neurofibromatosis 1 and 2.

Authors:  David H Gutmann; Marco Giovannini
Journal:  Neoplasia       Date:  2002 Jul-Aug       Impact factor: 5.715

10.  Merlin inhibits Wnt/β-catenin signaling by blocking LRP6 phosphorylation.

Authors:  M Kim; S Kim; S-H Lee; W Kim; M-J Sohn; H-S Kim; J Kim; E-H Jho
Journal:  Cell Death Differ       Date:  2016-06-10       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.